drugset / Trial / NCT00207766

A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease

NCT00207766

Phase 3 Completed 306 enrolled Centocor, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A study of infliximab in patients with Fistulizing Crohn's Disease

Timeline

Start
2000-06
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous

Indications